H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Humanigen on Friday, setting a price target of $36, which is approximately 58.31% above the present share price of $22.74.
Pantginis expects Humanigen to post earnings per share (EPS) of -$1.25 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Humanigen, with an average price target of $32.8.
The analysts price targets range from a high of $40 to a low of $21.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $486 thousand and a net profit of -$64.4 million. The company's market cap is $1.34 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 35.4% and a 55.43% success rate.
Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.